Unicycive Therapeutics Inc. has published a corporate presentation detailing its diversified pipeline focused on novel treatments for kidney disease. The company's lead asset, oxylanthanum carbonate (OLC), is being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The New Drug Application (NDA) for OLC was resubmitted following progress in resolving FDA-cited deficiencies with a third-party manufacturing vendor, and a new PDUFA date is expected in the first half of 2026. Unicycive reports that OLC, if approved, will offer a smaller tablet that can be swallowed whole, distinguishing it from the reference-listed drug Fosrenol. The company also highlights ongoing development of UNI-494 for acute kidney injury. Unicycive states that recent developments in the reimbursement landscape have expanded the market opportunity for OLC, with the US market for hyperphosphatemia treatments estimated at over $1 billion. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.
Comments